SELLAS Life Sciences Group Inc.
SLS | NASDAQ
$11.66
+$0.29 (+2.55%)
Sep 22, 2026, 10:45 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -15.08 | -2.08 | -0.79 | -1.11 | -4.13 | -2.75 |
PEG Ratio | 0.30 | 0.03 | 0.02 | -0.02 | 0.11 | 0.03 |
PS Ratio | n/a | n/a | n/a | 45.77 | 11.26 | 24.28 |
PB Ratio | 5.80 | 6.72 | -3.69 | 9.44 | 4.21 | 1.65 |
P/FCF Ratio | -14.48 | -1.80 | -0.80 | -1.62 | -3.29 | -4.43 |
P/OCF Ratio | -14.48 | -1.80 | -0.94 | -1.92 | -3.29 | -4.43 |
OCF/S Ratio | n/a | n/a | n/a | -2.38K | -342.38 | -548.26 |
Debt / Equity Ratio | 0.01 | 0.11 | -0.11 | 0.19 | 0.04 | 0.04 |
Quick Ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 | 2.99 |
Current Ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 | 2.99 |
Asset Turnover | n/a | n/a | n/a | 0.05 | 0.29 | 0.04 |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -37.90% | -326.27% | 468.15% | -851.39% | -101.73% | -59.93% |
Return on Assets | -34.29% | -158.92% | -600.42% | -197.21% | -78.33% | -36.39% |
Return on Invested Capital | -39.34% | -295.45% | 535.63% | -723.28% | -115.55% | -50.07% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | 90% | 97.37% | 100% |
Net Profit Margin | n/a | n/a | n/a | -4.13K% | -272.36% | -881.95% |
Pretax Profit Margin | n/a | n/a | n/a | -4.13K% | -275.47% | -882.84% |
Operating Profit Margin | n/a | n/a | n/a | -4.2K% | -332.82% | -893.79% |
FCF Margin | n/a | n/a | n/a | -2.83K% | -342.38% | -548.26% |
EBITDA Margin | n/a | n/a | n/a | -3.15K% | -241.07% | -863% |
Add to Watchlist
Select watchlists to add or remove SLS